Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy. Oral complications may lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier predisposes to life-threatening septic complications during aplasia. The prevalence of an oral focus in febrile neutropenia has been reported in up to 30% of cases and also reduces quality of life. The basic strategies aim at pain relief and prevention of bacterial and fungal infectious complications. However, no effective causal prophylaxis or treatment of oral mucositis is widely accepted. The introduction of cytokines, eg granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) for oral mucositis may be particularly effective and offer a new and hopeful approach. At present, the optimal growth factor, best schedule, effective dosage and best mode of application is not known.
intake of fluid and nutrients. Moreover, the intact oral mucosa and normal saliva act as an important barrier against the ever-present oral microorganisms. Mucosal damage may then be exacerbated by colonisation of the affected area with abnormal bacterial flora. Disruption of the mucosal barrier opens the door to consecutive, often life-threatening infectious complications during neutropenia. [9] [10] [11] [12] From the patient's point of view, oral mucositis is one of the major distressing complications of cancer therapy. In addition, severe oral mucositis and subsequent complications may lead to a delay in cancer therapy and dosereduction of antineoplastic agents, which might result in an unfavourable outcome of the cancer treatment.
Although oral mucositis is a well known complication, there is no clearly defined prophylaxis or treatment of oral mucositis. 13 Supportive care for oral mucositis is mostly empirical. Few recommendations are based on results from controlled clinical trials.
In recent years, a new approach for prophylaxis and treatment of oral mucositis has been reported with systemic and topical use of cytokines, especially growth factors G-/GM-CSF, TGF-␤ and IL-11. This review discusses current strategies for prophylaxis and treatment of oral mucositis, with emphasis on the introduction of cytokines for oral mucositis.
Incidence and etiology of oral mucositis
Oral mucositis occurs with an overall incidence of about 40% in standard-dose chemotherapy regimens. 12, [14] [15] [16] [17] [18] Severity and extent may vary with the cytotoxic drugs used, means of application, and the extent of myelosuppression that is induced. 19, 20 Certain chemotherapeutic agents, eg 5-fluorouracil with or without folinic acid, doxorubicin, etoposide, vinblastine, taxanes and methotrexate are commonly associated with the development of oral mucositis, 21, 22 while oral complications are rare with treatment with other cancer drugs, eg asparaginase, carmustine. When compared to standard-dose regimens, mucositis is more frequent in intensified chemotherapy protocols as well as conditioning regimens for bone marrow and peripheral blood stem cell transplantation. [23] [24] [25] The incidence of oral mucositis (WHO grades I-IV) in dose-intensified treatment settings has been reported in up to 90% with a range of severe mucositis (WHO grade III/IV) from 10% to 78%. 7, 17, [24] [25] [26] [27] [28] [29] [30] [31] Severe oral mucositis can be accentuated in patients treated with concomitant chemo-radiotherapy for head and neck cancer. In addition, susceptibility to cytotoxic drugs differs between different mucosal tissues ( Table 1) .
Course of oral mucositis
Mucositis usually starts 5-7 days after the onset of chemotherapy and first presents with erythema of the soft palate, 11 the buccal mucosa, the ventral surface of the tongue, and the floor of the mouth. 32 Erythema is frequently followed by edema and ulceration, ranging from aphthous-like lesions to generalised desquamation, maximal on days 11-14. 11,17 Over 90% of ulceration is localised to non-keratinized mucosa. 32 Oral ulceration has been reported to occur in patients receiving bone marrow transplantation for a median of 6 days. 32 However, it may persist for longer if graft-versus-host disease is present. 32 Histologically, dysplasia, hyperplasia, glandular degeneration, and collagen disruption have been documented. 33 A close relationship between radiation and acute as well as chronic changes in the oral environment is well known. Both can ultimately lead to soft tissue pathology. 34, 35 If natural teeth are present, the borders of the tongue may become serrated. Mucositis may be limited in range or can involve up to more than 50% of the oral cavity.
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Pathophysiology
The oral cavity is inhabited by large quantities and varieties of normal and opportunistic pathogens. These pathogens consist mainly of anaerobic bacteria. Out of the aerobic bacteria, viridans streptococci are of particular importance. Defences against oral microorganisms are multifactorial. A reduction in salivary gland and mucous gland function results in fewer secreted humoral factors (Ig A) in the saliva. 37 Disruption of the intact mucosa tissue and impairment of the mucosal barrier is considered to be an important risk factor for infection in the neutropenic host. [9] [10] [11] [12] With the frequent use of antibacterial prophylaxis for patients with prolonged neutropenia, a decreasing frequency of bacterial infections is observed in patients with oral mucositis. 38 However, the prevalence of an oral focus in febrile septicaemia has been reported in 25-50%. 10, [39] [40] [41] Mucositis in the oral cavity predisposes neutropenic cancer 10, 42 Streptococcus oralis and Streptococcus mitis are the two most common isolates from blood cultures and both are normal residents in the oral cavity. 43 Streptococcus viridans isolation in blood cultures is associated closely with the onset of oral mucositis. [44] [45] [46] Bacteremia with viridans streptococci occurred even a day before fever in about 24% of patients and was found in up to 70% as mucositis progressed to peak severity. 43 Prevalence rates of members of enterobacteriacae and streptococci have been reported as higher on days 8-12 in the oral cavity in patients with septicaemia when compared to those without febrile septicaemia. 10, 47 The oral cavity can also be a reservoir for multiple drug-resistant S. epidermidis, Stomatococcus mucilaginosus. 48 At present, it is controversial whether the reported upward trend of gram-positive bacteremia in febrile neutropenia is related to an increase in oral mucositis or the broader use of central venous lines. [48] [49] [50] The role of surveillance cultures of the oral cavity remains uncertain in this situation. They may be helpful for further identification of infectious foci. However their significant expense limits routine use for all patients with mucositis and neutropenia. 51 In contrast to bacterial infections, the incidence of invasive mycosis has increased over the last 20 years in cancer patients with oral mucositis. 52, 53 Severe mucositis is considered to be a risk factor for superficial as well as invasive yeast infections. 54 Almost all cases of systemic candidiasis originate from the oral cavity. 38 Candida albicans is encountered most frequently, but other species are seen in addition, eg C. tropicalis, C. krusei, C. parapsilosis, C. glabrata, Mucor, and Aspergillus spp. 16, 36, 51, [55] [56] [57] The appearance of superficial oral candida infection may vary from discrete white spots to extensive pseudomembranous lesions.
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Role of neutrophils in oral mucositis
Neutrophils can be considered the primary line of host defence against bacterial infection in the oral cavity. The importance of neutrophils in mucositis is illustrated by the onset of oral ulceration in patients with severe neutropenia. A well known clinical observation is the healing of oral mucositis prior to neutrophil recovery in the peripheral blood. 32, 33 Lieschke et al 58 observed neutrophils in oral mouthrinses 1-3 days before the neutrophils increased in the circulation above 0.1 ϫ 10 9 /1 after bone marrow transplantation and treatment with G-CSF. Recruitment of neutrophils for oral infection is considered to be the key of this observation.
Prophylaxis and treatment of oral mucositis
Oral health status and oral hygiene measures
Poor oral hygiene with concomitant dental and periodontal pathology has been associated with an increased incidence of infectious oral complications and mucositis during cancer treatment. 36, [59] [60] [61] [62] [63] [64] Therefore, instruction and motivation in the use of oral hygiene measures, including soft-bristled toothbrushes, dental floss and mouthwashes is recommended. If severe oral mucositis makes tooth brushing impractical, chlorhexidine soaked foam brushes may provide a valuable alternative in maintaining oral hygiene. 56 Good oral health status is also important for prevention of severe oral complications during antineoplastic therapy. 17, 65 A comprehensive oral evaluation prior to cancer therapy is highly warranted for this reason. Oral disorders, including dental plaque formation, third molars, periapical pathology periodontal disease, dental caries, defective dental restorations, ill-fitting prostheses, orthodontic appliances and other potential sources of mucosal and gingival irritation should be treated whenever possible. 66, 67 In addition, dentures should be removed during the night and should be cleaned meticulously, using a dental brush and antiseptic solutions. 36 
Mouthrinses with anti-infective and anesthetic properties
In practice, a wide variety of mouthrinses with anti-infective, and anesthetic properties are generally used for the treatment and prophylaxis of oral mucositis 68, 69 (see Table 2 ). These local measures include eg sodium-bicarbonate or hydrogen-peroxide solution, plant extracts such as glycerine-thymole or glycerine-lemon, camomile, sage and myrrh. In addition, medical mouthwashes such as chlorhexidine, PVP-iodide 70 or benzydamine have been evaluated in clinical studies. Results from controlled trials with myrrh tincture and sage solution are not available.
Glycerine-thymole and glycerine-lemon rinses seem to be no more effective than saline solution. 71 Treatment of oral mucositis with sodium-bicarbonate and hydrogen-peroxide may even be harmful due to an alteration of the pH, resulting in disturbance of mucosal regeneration. 72, 73 Controlled studies with chlorhexidine reported an improvement of oral hygiene with reduction of potential bacterial and fungal pathogens, especially yeasts, and decreased plaque formation. However, the impact of chlorhexidine regarding healing of oral mucositis is unproven. Several topical and systemic antifungal agents have been studied in patients receiving treatment for acute leukaemia or stem cell transplantation. Controlled randomised studies with oral amphotericin B, fluconazole or intraconazole reported a reduction of yeast colonisation and superficial candida infections which may aggravate oral mucositis. 74 Topical benzydamine is reported to be useful in topical pain control. Benzydamine is a nonsteroidal anti-inflammatory agent with antimicrobial and anaesthetic properties. However, initial severe oral stinging decreases patient compliance and may require additional topical anaesthetics. 75 Therefore, the beneficial effect of benzydamine seems to be questionable.
Furthermore, topical anaesthetics are used in severe oral mucositis. These modalities include viscous lidocaine, cocaine rinses and spray, dyclonine and capsaicin, the active agent of chilli peppers, which desensitises pain receptors. [76] [77] [78] These agents provide temporary pain relief. The topical use of a bioadhesive hydroxypropyl-cellulose (HPC)-based film is a newer approach which aims at pain control by providing a protective shield over oral ulceration. 79 In addition, soluble components of the HPC-based film (Zilactin) have reported in vitro virucidal activity against herpes simplex virus-1 (HSV-1). HSV infection may occur with deep oral ulceration.
Medications with anti-ulcerative properties have been studied in patients with oral mucositis. However, the results were discouraging. Topical use of sucralfate may reduce local pain in oral mucositis; however, its reported efficacy in treating oral ulceration is controversial. [80] [81] [82] Prostaglandins and pentoxifylline were investigated, and have a marginal effect on oral mucositis. [83] [84] [85] These agents may even be hazardous due to a reported increase of infections. [86] [87] [88] [89] Topical azelastine seems to improve clinical symptoms in patients with aphtous ulceration and Behcets disease; however, the effect in oral mucositis is only accessible from one study. 90 Use of allopurinol mouthwashes for prophylaxis of 5-flurouracil-induced oral mucositis was studied with the hypothesis of inhibiting orotidylate decarboxylase which produces a toxic metabolite of 5-FU. In addition, allopurinol inhibits superoxide dismutase activity and suppresses proteases. 91 However, no benefit was proven in clinical trials. 92, 93 Leucovorin is routinely used for rescue after high-dose methotrexate (MTX). Animal studies have suggested a cytoprotective effect on enteritic cells. Oliff et al 94 observed a relationship between MTX plasma levels and simultaneous MTX saliva levels in humans. However, they could not demonstrate a correlation between saliva levels and oral mucositis or an effect of leucovorin mouthwash for the reduction of oral mucositis. Results of controlled studies on the efficacy of leucovorin for MTX-induced mucositis are not available.
Another therapeutic approach is dietary supplementation. In animal studies, a glutamine-enriched diet was shown to ameliorate chemotherapy-induced enterotoxicity. Results reported from clinical trials with supplementation of glutamine in patients with oral mucositis are controversial, since transfer of these observations from an animal model to clinical trials could not be proven. [95] [96] [97] Systemic application of ␤-carotene for prophylaxis, 98 and topical application of tocopherole 99 for treatment of oral mucositis has been reported as beneficial. Confirmation of these trials is necessary.
Topical laser irradiation 100, 101 and brushing of the oral mucosa with silver-nitrate 102, 103 seem to be promising for prophylaxis of oral complication after chemotherapy. Silver 34 G-CSF 5 g/kg rd CT ϩ (P = 0.07) BMT = bone marrow transplantation; co = cross-over; CT = chemotherapy; hc = historical control; HD-CT = high-dose chemotherapy; om = oral mucositis; nrd = non-randomised; nc = no control; PBSCT = peripheral blood stem cell transplantation; r = randomised; RT = radiotherapy; SCT = stem cell transplantation; NA =data not available.
nitrate stimulates cell proliferation in the basal layer prior to cancer therapy and may thereby overcome the discrepancy between cell killing and cell proliferation. Efficacy related to propantheline in the prophylaxis of etoposide-induced oral mucositis has been shown. 29, 104 Since etoposide is secreted in saliva, the parasympatholytic agent propantheline may reduce the secretion of etoposide in the saliva and the concentration of etoposide in the oral cavity. Oral cryotherapy during chemotherapy can cause local vasoconstriction in the mouth and may reduce the uptake of chemotherapeutic agents with a short half-life into mucosa cells. Cryotherapy attenuated severity of oral mucositis under bolus application of methotrexate (MTX), 5-fluorouracil or melphalan.
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Cytokines for prophylaxis and treatment of oral mucositis
G-/GM-CSF
In patients with oral mucositis, earlier neutrophil recovery due to systemic G-/GM-CSF use may play an important role. Improved chemotaxis, phagocytosis and intracellular oxygen metabolism of neutrophils triggered by G-CSF can be suggested in addition. An enhanced host macrophage capacity and neutrophil function after myelosuppressive chemotherapy and treatment with GM-CSF may also contribute to a reduction of duration, as well as severity, of mucositis. 110 The relationship between peripheral neutrophils and neutrophils in the oral cavity is well known. 33, 58 Clinical improvement of oral mucositis precedes recovery of peripheral blood neutrophil counts. This resolution of oral mucositis seems to contribute to a migration of neutrophils to the oral cavity.
G-and GM-CSF belong to a family of glycoprotein growth factors. 111, 112 They promote the proliferation and differentiation of neutrophil and monocyte/macrophage precursors. Systemic use (s.c. or i.v.) of G-/GM-CSF has been proven to accelerate the recovery of neutrophils to normal levels after myelosuppressive chemotherapy. [113] [114] [115] [116] [117] The action of G-/GM-CSF was thought to be initially restricted to haematopoiesis alone. Laboratory studies have shown however, that G-/GM-CSF influence proliferation and migration of non-haematopoietic cells, including endothelial cells 118 and keratinocytes, 119 suggesting that they may act as regulatory signals outside the haematopoietic system. Clinical studies using subcutaneous G-CSF or GM-CSF have shown a beneficial effect on oral mucositis 110, [120] [121] [122] [123] [124] [125] [126] ( Table 3 ). In addition to the amelioration of severe and long-lasting neutropenia, systemic G-CSF or GM-CSF activates neutrophil migration, chemotaxis, phagocytosis and cytotoxicity. 127 In addition, G-/GM-CSF may exert an effect on epithelial cell proliferation of the oral mucosa via the paracrine mechanisms of fibroblasts. However the precise mechanisms are unknown.
Topical application of G-CSF appears beneficial with respect to incidence and course of methotrexate-induced mucositis and associated complications. 11 Data from pilot studies of topical GM-CSF for prophylaxis and treatment of oral mucositis are also available (Table 4) . [128] [129] [130] [131] [132] [133] Topical treatment with GM-CSF enhanced wound contraction and healing of contaminated wounds in animal models. 134 Some studies have been supportive of systemic and oral use of CSF. However, there are a number of randomised studies that have not shown a benefit of haematopoietic growth factors in ameliorating oral mucositis. Since the underlying mechanism of action of haematopoietic growth factors in patients with mucositis remains poorly understood, further clinical investigations are necessary.
Transforming growth factor beta (TGF-␤)
Members of the TGF-␤ family, especially TGF-␤ 1 and 3 are involved in the process of wound healing. They increase the synthesis and deposition of the extracellular matrix including collagen deposition, stimulate migration of mononuclear cells and fibroblasts across wound margin and induce cell differentiation. [135] [136] [137] Disturbances in the finely balanced ratio between the different members of the TGF-␤ superfamily lead to scarring and fibrosis. 138 The topical application of TGF-␤ to skin wounds results in increased breaking strength and accelerated wound healing. 139 TGF-␤ 3 inhibits cell cycle progression through G1. 140 In an animal model for radiation-induced small intestine damage, Potten et al 140 could demonstrate a fourto six-fold increase in survival of small intestinal crypts and a significantly increased survival of animals, if TGF-␤ was administered over a 24 h period prior to irradiation.
The topical application of TGF-␤ to oral mucosa results in significantly reduced basal cell proliferation in vitro and in vivo. 141 In an animal model for chemotherapy-induced oral mucositis topical TGF-␤ resulted in decreased incidence, severity and duration of oral mucositis, in reduced weight-loss and increased animal survival. 141, 142 Since an efficacy of TGF-␤ could not be proven in early clinical trials, TGF-␤ has been withdrawn from further clinical development for oral mucositis.
Keratinocyte growth factor (KGF)
KGF is a member of the fibroblast growth factor family. This cytokine seems to specifically act on epithelial cells, inducing proliferation, differentiation and migration. [143] [144] [145] After skin injury mRNA transcription for KGF is induced in the dermis of the wound margin and in the hypodermis below the wound ground. Messenger RNA for the KGF receptor is induced in the epidermis. 143 These results are in line with a study by Takahashi et al, 144 who could show KGF mRNA in fibroblasts but not epithelial cells.
In an animal model, single topical use of KGF at the time of skin wounding increases wound breaking and tensile strength, epidermal thickness and wound collagen content. Healing of intestinal anastomoses could be increased by systemic application of KGF after surgery. 146 Zeeh et al 147 demonstrated a significant amelioration of tissue damage in a model of colitis, if KGF was administered after induction of colitis, whereas application prior to induction had no beneficial effect. In contrast, Farrell et al 148 found increased survival, amelioration of weight loss, increased mucosal thickness and a 3.5-fold improved crypt survival in the small intestine after pretreatment of animals prior to chemotherapy, radiotherapy or combined treatment modalities. KGF administration before conditioning ameliorates GVHD-induced tissue damage in a murine allo-BMT model. 149 However, the hopeful effect of KGF on oral mucositis has not been investigated in clinical trials to date.
Interleukin-11 (IL-11)
In addition to its haematopoietic properties, IL-11 increases proliferation and partially suppresses apoptosis of intestinal mucosal cells. [150] [151] [152] Systemic administration of IL-11 in mice prior to CT, RT or combined CT/RT resulted in significantly increased survival, rapid recovery of the small intestine mucosa and increased villous length. 150, 151, 153 Additional application of IL-11 after RT only slightly enhanced this beneficial effect. 153 Sonis et al 154 showed a beneficial effect of systemic IL-11 on the oral mucositis of the Syrian golden hamster, treated with combined CT/RT. IL-11 application resulted in decreased incidence, severity and duration of oral mucositis. Recently a phase I study was published with IL-11 162 for the treatment of oral mucositis. IL-11 was well tolerated. Efficacy of IL-11 for the treatment of prophylaxis of oral mucositis, however, has to be proven in randomised trials.
Conclusion
Some approaches seem promising for prophylaxis or treatment of oral mucositis. However, these are limited to patients who have received selected chemotherapy regimens, eg local cryotherapy in MTX or melphalan bolus application and propantheline for etoposide-induced oral mucositis. Preliminary results with soft-laser treatment 161 and the use of silver-nitrate are encouraging. Although granulocytes play an important role in the onset and development of oral mucositis, acceleration of neutrophil recovery and function by use of haematopoietic growth factors (G-/GM-CSF) may have a small effect on oral mucositis. Since oral mucositis is a major dose-limiting toxicity, there is a need for larger randomised trials to evaluate the beneficial effect of growth factors for prevention or treatment of oral mucositis.
